Description

Pyrazino(1,2-A)(1,4)Benzodiazepine, 1,2,3,4,4A,5-Hexahydro-3-(3-Methyl Butyl)-7-(2-Thienyl)-, Dihydrochloride is a complex heterocyclic organic compound with a fused benzodiazepine and pyrazine ring system, modified with a thienyl substituent and isolated as a dihydrochloride salt. This specific molecular architecture makes it a valuable advanced pharmaceutical intermediate for research into novel therapeutic agents. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the synthesis of bioactive molecules targeting the central nervous system and other therapeutic areas.

Application

• Pharmaceutical Intermediate: Key building block in the research and development of new active pharmaceutical ingredients (APIs), particularly for neurological and psychiatric applications.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies to explore and optimize the biological activity of benzodiazepine-derived compounds.
• Preclinical Drug Development: Serves as a critical material for synthesizing candidate compounds for pharmacological screening and toxicology studies.
• Reference Standard: Can be utilized as a high-purity analytical standard for method development and quality control in API manufacturing.
• Chemical Biology Probes: Potential use in developing molecular probes to study specific biological pathways and receptor interactions.

Basic Information

Product Name	Pyrazino(1,2-A)(1,4)Benzodiazepine, 1,2,3,4,4A,5-Hexahydro-3-(3-Methyl Butyl)-7-(2-Thienyl)-, Dihydrochloride
CAS No.	105138-51-0
Molecular Formula	C22H27N3OS • 2HCl
Molecular Weight	454.45 g/mol (free base: 381.54 g/mol)
Synonyms	1,2,3,4,4a,5-Hexahydro-3-(3-methylbutyl)-7-(2-thienyl)pyrazino[1,2-a][1,4]benzodiazepine dihydrochloride; 7-(2-Thienyl)-3-(3-methylbutyl)-1,2,3,4,4a,5-hexahydropyrazino[1,2-a][1,4]benzodiazepine dihydrochloride; Thienyl-substituted hexahydropyrazinobenzodiazepine dihydrochloride; CAS 105138-51-0
EINECS	Contact for details

Quality Control

Our production of this high-purity pharmaceutical intermediate adheres to stringent quality protocols. Every batch undergoes comprehensive analytical testing, including HPLC for purity and identity confirmation (NMR, IR, MS), to ensure it meets exacting research-grade specifications. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting batch-specific results. We operate under a cGMP-compliant quality management system to ensure traceability, consistency, and reliability for critical R&D applications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This compound is hygroscopic (moisture-sensitive); therefore, the container must be kept tightly sealed in a dry environment to prevent degradation. For long-term storage, consider desiccated conditions.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (HPLC)	Conforms to reference standard
Identification (IR)	Conforms to structure
Purity (HPLC)	≥ 98.0%
Water Content (KF)	≤ 1.0%
Residue on Ignition	≤ 0.5%
Heavy Metals	≤ 20 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 2.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.